Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations.
about
Insomnia pharmacotherapyInsomniaStrategic opportunities in sleep and circadian research: report of the Joint Task Force of the Sleep Research Society and American Academy of Sleep MedicineImplementation of Sleep and Circadian Science: Recommendations from the Sleep Research Society and National Institutes of Health WorkshopThe impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trialEffects of anesthesia on the response to sleep deprivationThe effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study.A randomized, double-blind, placebo-controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain.A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomniaWhy treat insomnia?Benzodiazepine receptor agonists cause drug-specific and state-specific alterations in EEG power and acetylcholine release in rat pontine reticular formationManagement of Hypnotic Discontinuation in Chronic Insomnia.Hippocampal adult neurogenesis is enhanced by chronic eszopiclone treatment in rats.Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo.Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia.Aerobic exercise improves self-reported sleep and quality of life in older adults with insomniaTwelve months of nightly zolpidem does not lead to dose escalation: a prospective placebo-controlled studyNeuropharmacology of Sleep and Wakefulness.Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem.Insomnia and the performance of US workers: results from the America insomnia survey.The association of fatigue with depression and insomnia in HIV-seropositive patients: a pilot study.Patient Background Factors Affecting the Therapeutic Outcomes in Response to Eszopiclone in Adult Patients with Chronic Insomnia: A Post Hoc Analysis of a Double-Blind Phase III Study in Japan.Effects of eszopiclone on safety, subjective measures of efficacy, and quality of life in elderly and nonelderly Japanese patients with chronic insomnia, both with and without comorbid psychiatric disorders: a 24-week, randomized, double-blind studyEfficacy of eight months of nightly zolpidem: a prospective placebo-controlled study.Neuropharmacology of Sleep and Wakefulness: 2012 Update.Eszopiclone treatment for insomnia: effect size comparisons in patients with primary insomnia and insomnia with medical and psychiatric comorbidity.Quality of life in patients suffering from insomniaEszopiclone versus zopiclone in the treatment of insomnia.Gender Differences in the Efficacy and Safety of Chronic Nightly Zolpidem.Relationship between sleep disturbance and recovery in patients with borderline personality disorderAn approach to long-term sedative-hypnotic useA polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia.Zolpidem extended-release 12.5 mg associated with improvements in work performance in a 6-month randomized, placebo-controlled trial.Measures of sleep in rheumatologic diseases: Epworth Sleepiness Scale (ESS), Functional Outcome of Sleep Questionnaire (FOSQ), Insomnia Severity Index (ISI), and Pittsburgh Sleep Quality Index (PSQI).Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomniaOptimizing the Pharmacologic Treatment of Insomnia: Current Status and Future HorizonsCost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia.Sleep duration and health-related quality of life among older adults: a population-based cohort in Spain.Sleep and sleep disorders in chronic users of zopiclone and drug-free insomniacs.Algorithms for the assessment and management of insomnia in primary care.
P2860
Q24623757-A25D69CD-3991-4177-B949-556E3930C886Q24632498-E36AA1B7-4B61-444F-8C2E-6B7FE19646A7Q26858809-5A854271-A52F-486C-B742-84C4E8F078A7Q28393831-F0056ACB-C04B-464C-972F-3C5A2359D474Q30301208-9383D3C8-D93D-4A16-BF19-7A43A6DF1B63Q30475357-D46775EA-E095-4945-86F9-DEB97CB6E2C7Q33586991-57B08E0F-C94F-47B1-A4F1-3CF1E05F9963Q33587570-2D28ADAD-6E69-49DA-9D2C-84DACFA343DBQ33635442-71FD49EF-D2A4-49BC-BA19-6BD93E8FC093Q33902276-F9F66B7B-613B-4AB9-B7A6-B279897F3D0BQ33950189-8A9EBCB5-7E50-4E44-821E-8DBE95CB7B9FQ33958179-74396ABF-BA07-4084-A95D-7EF395A690DCQ34061181-E1801925-23E3-4235-ADC9-8CE1AE36896CQ34086489-2FCC7394-1728-4BF2-9511-3FEC48D024B4Q34197699-70546434-A28A-4B03-B54E-CE00608B7824Q34355630-54CC4EA7-E6DE-4755-9CB4-E895622BF2FAQ34500442-E9BF4C08-D76C-401D-9F32-1E1AC923D0C2Q34518670-2CCF6C71-C8D8-4FCF-834B-D58A32B077D2Q35016391-A6642B9A-2F05-4C4B-B1A6-A8B9541E8CA4Q35169400-314A2EA6-D663-43B6-B7F1-48FD3D57A083Q35529548-926F7100-6658-4669-B8F9-1C8B773061EEQ36090682-F05DB9FA-720D-4177-939C-F6F7621A3F5FQ36198401-6E18A120-DE45-48E2-998C-49136531EDD9Q36304821-E28104AC-C49E-43BE-B38B-B34E5C505AE6Q36393701-939DF8B1-1B22-4BBE-9D4A-6FB3E496BAB3Q36419739-828EE82F-B0D2-40AD-B6DC-039C085BE7B1Q36430588-F88CA945-18ED-46E2-968A-008961FA3B93Q36518854-B8F984E6-CBE2-4D6A-B932-B3DAAB191B04Q36637811-8C09B195-0BA0-46AF-8996-11A4A60AA210Q36701876-EBCF94B1-D1A2-4A1A-932F-C83CD3218925Q36779890-102977A2-BDF0-4B1F-8FF7-66537A22ECADQ36897384-25FBE368-C62E-49B5-AD0F-C8CC0A811656Q36948426-3642FBBB-CCDB-45CB-A98B-C330990CD7B7Q37011902-7784E809-7DE0-41CA-AD6F-F152D9B9F599Q37109731-792966C0-E7EA-4528-9C89-1701C173CDECQ37149325-EE83AE5A-B8CC-49BB-B8E2-79562603DAD8Q37212670-16943AA7-4566-4B62-A13A-2335D3F3E6DBQ37279102-D1F92B19-E7CA-4B01-BB79-5828893C6485Q37301240-306B6935-7DA0-404D-AAFD-C0F76EC4164DQ37423760-067BD145-A48E-405A-AC4D-D27D28FC2796
P2860
Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Nightly treatment of primary i ...... of life, and work limitations.
@ast
Nightly treatment of primary i ...... of life, and work limitations.
@en
type
label
Nightly treatment of primary i ...... of life, and work limitations.
@ast
Nightly treatment of primary i ...... of life, and work limitations.
@en
prefLabel
Nightly treatment of primary i ...... of life, and work limitations.
@ast
Nightly treatment of primary i ...... of life, and work limitations.
@en
P2093
P2860
P1433
P1476
Nightly treatment of primary i ...... of life, and work limitations.
@en
P2093
Andrew D Krystal
David A Amato
Gene Wallenstein
James K Walsh
James Roach
Judy Caron
Kendyl Schaefer
Robert Rubens
Thomas C Wessel
Thomas Roth
P2860
P304
P577
2007-08-01T00:00:00Z